Business Wire

The Estée Lauder Companies Announces Brand Leadership Promotions

1.7.2021 15:30:00 EEST | Business Wire | Press release

Share

The Estée Lauder Companies (NYSE:EL) announced today the promotions of two brand leaders – Michelle Freyre has been promoted to Global Brand President, Clinique, and Glenn Evans has been promoted to Global Brand President, Smashbox and GLAMGLOW. The promotions are effective July 1, 2021, and both leaders will continue to report directly to John Demsey, Executive Group President, The Estée Lauder Companies (ELC).

“Michelle and Glenn are both incredibly dynamic leaders who have beautifully steered their respective brands through the challenges of the past year,” said John Demsey. “I am particularly proud of how effectively they have balanced the needs of the business while being truly thoughtful and empathetic leaders to their brand teams. Their promotions are both very well-deserved.”

Michelle Freyre Has Been Promoted to Global Brand President, Clinique

A dynamic leader with deep experience leading a variety of beauty brands across categories and channels, Michelle’s promotion to Global Brand President, Clinique, recognizes her outstanding and visionary leadership in returning Clinique to global growth. She was appointed Senior Vice President/Global General Manager, Clinique in June 2020, and since then has made a significant impact on Clinique’s brand positioning, driving double digit growth for hero products, as well as redefining the innovation strategy behind Clinique’s hero franchises. She has also driven Clinique’s acceleration in Online to be the #1 ELC brand in North America in that channel, while delivering the Clinique High-Touch experience at scale globally. Her inspirational leadership, deep expertise in beauty and skin care, together with her strong passion for connecting with global consumers, makes her uniquely suited to continue to lead Clinique in its next chapter of growth.

Michelle joined ELC from Johnson & Johnson in 2020, where she had an impressive 20-year career holding various leadership roles within its Consumer Health Products division, most recently serving as President, U.S. Beauty. In this role, she was responsible for the company’s portfolio of Beauty brands at the time, and led the successful performance and growth of many brands. Prior to that, she served as the General Manager of Neutrogena at J&J, and as the leader of the company’s Los Angeles campus.

Michelle is passionate about talent development and has a proven track record of fostering workplaces that embrace inclusion and diversity. She has received several industry awards and honors in recognition of her exceptional career, including being named to Fortune’s 2018 “50 Most Powerful Latinas in Business.”Michelle is the Executive Sponsor of Hispanic Connections (HiC) ERG and is actively mentoring diverse talent across ELC.

Glenn Evans Has Been Promoted to Global Brand President, Smashbox and GLAMGLOW

With more than 30 years of strategic, operational and brand-building experience, Glenn is an exceptional, values-driven brand leader with an impressive track record of delivering consistent results. As Senior Vice President/Global General Manager, Smashbox and GLAMGLOW, Glenn has successfully led both brands, capturing operational and supply chain synergies between them, optimizing their global brand and regional go-to-market structures and improving A&P effectiveness.

As Global Brand President, Glenn will continue to lead Smashbox and GLAMGLOW into their next phases of sustainable growth, focusing on product innovations with a consumer-led, online-centric, digital-first approach, as well as continuous transformation to evolve ahead of the changing retail landscape. A dynamic and energetic leader, Glenn will also continue to leverage his passion for developing top talent across both brand teams.

Since being named Senior Vice President and General Manager, Smashbox, in 2019, Glenn has led the brand’s repositioning strategy to drive appeal with both new and loyal consumers while staying true to the brand’s core studio heritage. Under his leadership, the brand reinforced its number one ranking in U.S. prestige Face Primers, achieved top rankings in prestige Face Primers in key global markets, and attracted new consumers with the success of Smashbox Halo All-in-One Tinted Moisturizer.

Before his role at Smashbox, Glenn was Senior Vice President, Leading Beauty Forward, where he led the successful global implementation of Leading Beauty Forward and OneSource, which have helped to fuel the company’s multiple engines of growth strategy. Prior to that role, Glenn was SVP, Global Supply Chain, during which time he established and led the Global Supply Chain Center of Excellence for six years, and played a leadership role in integrating and enhancing best-in-class capabilities across the organization.

Since 2018, Glenn has served as an Executive Sponsor of wELCome, ELC’s Employee Resource Group for LGBTQIA+ employees. He continues to act as a passionate advocate for Inclusion & Diversity across the Company. Glenn recently announced the creation of the West Coast chapter of wELCcome and he also sponsors the Smashbox & GLAMGLOW Multi-Ethnic Advisory Board, an employee-led group within the brands that aims to ensure diverse voices are amplified during key moments of decision-making.

About The Estée Lauder Companies Inc.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, Tommy Hilfiger, M·A·C, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin Paris, TOM FORD BEAUTY, Smashbox, Ermenegildo Zegna, AERIN, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, BECCA, Too Faced and Dr.Jart+, and the DECIEM family of brands, including The Ordinary and NIOD.

ELC-C
ELC-L

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Investor Relations:
Rainey Mancini
(212) 284-3049
rmancini@estee.com

Media Relations:
Jill Marvin
(212) 572-4438
jimarvin@estee.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye